Resultado de búsqueda
29 de may. de 2024 · This phase 2, single arm, European multi-center trial was designed to evaluate the efficacy of afatinib as first- or later-line tyrosine kinase inhibitor (TKI) treatment in advanced chordoma. Here we report efficacy and safety data.
18 de may. de 2024 · The phase 2 ASCENT trial assessed the efficacy and safety of afatinib and concurrent chemoradiotherapy with or without surgery in locally advanced epiderma
29 de may. de 2024 · Results in a small cohort of pts with advanced solid tumors with NRG1 fusions treated with afatinib are reported. Methods: Eligible pts had measurable, advanced disease, NRG1fusion, ECOG performance status (PS) 0-2, adequate organ function, and no standard treatment (tx) options.
18 de may. de 2024 · Subsequently, Boehringer Ingelheim sponsored a large-scale pooled analysis from 15 studies (prospective trials, cohort studies, case series, case reports, patient assess programs) to further assess the clinical activity of afatinib in “uncommon” EGFR mutations.
28 de may. de 2024 · La Fase II, realizada en 2022 en servicios de Cardiología y Medicina Interna sin unidades de IC acreditadas, ha puesto de manifiesto diferencias en el manejo de la IC en hospitales sin unidades de IC acreditadas, donde el 83% disponen de hospital de día y un 62% enfermería especializada, un porcentaje significativamente inferior 1.
Hace 6 días · Copenhagen, Denmark, June 6, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) today announced that an embargoed abstract of positive results from Boehringer Ingelheim’s Phase 2 trial of survodutide (BI...
3 de jun. de 2024 · Treatment with 80 mg once daily osimertinib achieved a median OS of 15.0 months and an objective response rate of 51.6%, alongside a disease control rate of 81.3% in the efficacy-evaluable set as assessed by blinded independent central review, underscoring significant intracranial activity.
